MGB Biopharma, established to develop a new class of anti-infective medicines, has raised the cash in a round which included the Scottish Investment Bank.

The Pharmstandard-backed pharmaceutical company is seeking to raise the cash in an IPO four months after it closed part of a $45m series D round.

The Novartis-backed pharmaceutical company will use the proceeds to fund pivotal tests for its prostate cancer drug.

Healthcare management technology company TriZetto has been acquired by IT and consulting company Cognizant Technology Solutions for $2.7bn.

The non-profit healthcare provider will invest in early and mid-stage companies in order to spur technology that can improve medical care.

Medical company Acusfoucs has added $21m in capital as it waits for approval from the FDA on its Kamra inlay, which is designed to treat near-vision loss.

Biotechnology company Scholar Rock has raised $20m in a series A round featuring Kraft Group that will fund the development of novel biologic therapeutics.

Medical device company Esco has launched a venture capital fund targeting the life sciences, medical and healthcare technologies sectors, which will invest $8m over a three-year period.

BlueCross BlueShield has contributed to a $6m second tranche of Lumiata's series A round.

The cancer drug developer, which counts Novo Nordisk among its shareholders, floated below its range, but issued a larger number of shares than expected.